Market news

On August 6, Artivion Inc. (NYSE:AORT) reported second-quarter 2026 results that read as if two different companies wrote them. Revenue for the quarter ended June 30 climbed 11% on a GAAP basis to $125.8 million, and the company finished assembling what it calls the only complete aortic arch portfolio in its industry. Yet the same […]

Andrew M Green, Senior Vice President, Regulatory and Quality, on September 10, 2026, sold 11,480 sh

Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. With the Discounted Cash Flow (DCF) estimate and market multiples both pointing to pricing that looks broadly in line with fundamentals, the stock no longer looks obviously cheap or obviously expensive. Artivion is up 57.6% over three years. This means anyone looking at the stock today is...

Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026. Artivion’s recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers. Balance...

Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on the stock to $40 from $39 while maintaining a Buy rating.

Detailed price information for Artivion Inc (AORT-N) from The Globe and Mail including charting and trades.

Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve portfolios. Management credited strong On-X adoption, improved stent graft set sales, and a return to growth across international markets as key drivers behind the positive momentum. CEO Pat Mackin highlighted the recent FDA approval of the AMDS hybrid prosthesis and the acquisition of Endospan’s NEXUS system as important milestones, noting, “

Detailed price information for Artivion Inc (AORT-N) from The Globe and Mail including charting and trades.

5 Revealing Analyst Questions From Artivion’s Q2 Earnings Call

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Artivion (AORT) delivered earnings and revenue surprises of 0.00% and +4.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Detailed price information for Artivion Inc (AORT-N) from The Globe and Mail including charting and trades.

Artivion (AORT) is back on investors’ radar after new focus on its business model and capital efficiency, highlighting the company’s smaller revenue base, limited free cash flow, and ongoing return on capital challenges. See our latest analysis for Artivion. Recent price action has been mixed for Artivion, with a 1 month share price return of 14.6% coming after a 90 day share price decline of 20.9%, while the 3 year total shareholder return of 63.6% contrasts with weaker results over 1 year...

Detailed price information for Artivion Inc (AORT-N) from The Globe and Mail including charting and trades.

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]

Detailed price information for Artivion Inc (AORT-N) from The Globe and Mail including charting and trades.